Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Wang, Fang ^a   Yu, Bolan ^a   Yang, Wenjing ^b   Liu, Jianqiao ^a   Lu, Jiachun ^a   Xia, Xuefeng ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Ovarian; Polycystic ovary syndrome (PCOS); Prenatal androgenization; Rat model

Indexed keywords

ANDROGEN; ESTROGEN; PRASTERONE SULFATE;

ABORTION; ANDROGEN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ESTROGEN BLOOD LEVEL; FEMALE; FEMALE FERTILITY; HISTOPATHOLOGY; MICROSCOPY; NONHUMAN; OVARY POLYCYSTIC DISEASE; PREGNANCY; PRIORITY JOURNAL; PROGENY; RAT; REPRODUCTIVE TOXICITY; SURVIVAL RATE;

EID: 84861147497     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-15     Document Type: Article

References (26)

1. Polycystic ovary syndrome. Norman RJ, Dewailly D, Legro RS, Hickey TE, Lancet 2007 370 685 697 10.1016/S0140-6736(07)61345-2 17720020 (Pubitemid 47285318)
2. The prevalence and features of the polycystic ovary syndrome in an unselected population. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO, J Clin Endocrinol Metab 2004 89 2745 2749 10.1210/jc.2003-032046 15181052 (Pubitemid 38766360)
3. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R, J Clin Endocrinol Metab 1998 83 3078 3082 10.1210/jc.83.9.3078 9745406 (Pubitemid 28500937)
4. Polycystic ovarian disease: heritability and heterogeneity. Crosignani PG, Nicolosi AE, Hum Reprod Update 2001 7 3 7 10.1093/humupd/7.1.3 11212071 (Pubitemid 32111960)
5. Early Origins of polycystic ovary syndrome: hypotheses may change without notice. de Zegher F, Ibanez L, J Clin Endocrinol Metab 2009 94 3682 3685 10.1210/jc.2009-1608 19808859
6. Polycystic ovary syndrome and its developmental origins. Dumesic DA, Abbott DH, Padmanabhan V, Rev Endocr Metab Disord 2007 8 127 141 10.1007/s11154-007-9046-0 17659447 (Pubitemid 47434646)
7. Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys. Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW, Trends Endocrinol Metab 1998 9 62 67 10.1016/S1043-2760(98)00019-8 18406243 (Pubitemid 28207615)
8. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. Zhou R, Bird IM, Dumesic DA, Abbott DH, J Clin Endocrinol Metab 2005 90 6630 6637 10.1210/jc.2005-0691 16174719 (Pubitemid 41759326)
9. Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Wild RA, Umstot ES, Andersen RN, Ranney GB, Givens JR, Am J Obstet Gynecol 1983 146 602 606 6223527 (Pubitemid 13074492)
10. Premature adrenarche-normal variant or forerunner of adult disease? Ibanez L, Dimartino-Nardi J, Potau N, Saenger P, Endocr Rev 2000 21 671 696 10.1210/er.21.6.671 11133068 (Pubitemid 32113288)
11. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, Yoo R, Chang RJ, Foster CM, Caprio S, Marshall JC, J Clin Endocrinol Metab 2007 92 430 436 17118995
12. Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys. Abbott DH, Barnett DK, Levine JE, Padmanabhan V, Dumesic DA, Jacoris S, Tarantal AF, Biol Reprod 2008 79 154 163 10.1095/biolreprod.108.067702 18385445 (Pubitemid 351931028)
13. Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Abbott DH, Tarantal AF, Dumesic DA, Am J Primatol 2009 71 776 784 10.1002/ajp.20679 19367587
14. Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome. Bruns CM, Baum ST, Colman RJ, Dumesic DA, Eisner JR, Jensen MD, Whigham LD, Abbott DH, Int J Obes (Lond) 2007 31 1579 1585 10.1038/sj.ijo.0803638 (Pubitemid 47482655)
15. Early prenatal androgenization results in diminished ovarian reserve in adult female rhesus monkeys. Dumesic DA, Patankar MS, Barnett DK, Lesnick TG, Hutcherson BA, Abbott DH, Hum Reprod 2009 24 3188 3195 10.1093/humrep/dep324 19740899
16. Fetal programming: prenatal testosterone treatment leads to follicular persistence/luteal defects; partial restoration of ovarian function by cyclic progesterone treatment. Manikkam M, Steckler TL, Welch KB, Inskeep EK, Padmanabhan V, Endocrinology 2006 147 1997 2007 16373416
17. Fetal programming: excess prenatal testosterone reduces postnatal luteinizing hormone, but not follicle-stimulating hormone responsiveness, to estradiol negative feedback in the female. Sarma HN, Manikkam M, Herkimer C, Dell'Orco J, Welch KB, Foster DL, Padmanabhan V, Endocrinology 2005 146 4281 4291 10.1210/en.2005-0322 15976056 (Pubitemid 41324024)
18. Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Veiga-Lopez A, Steckler TL, Abbott DH, Welch KB, MohanKumar PS, Phillips DJ, Refsal K, Padmanabhan V, Biol Reprod 2011 84 87 96 10.1095/biolreprod.110.086686 20739662
19. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Demissie M, Lazic M, Foecking EM, Aird F, Dunaif A, Levine JE, Am J Physiol Endocrinol Metab 2008 295 262 E268 10.1152/ajpendo.90208.2008 18544644
20. Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague-Dawley rats. Wu XY, Li ZL, Wu CY, Liu YM, Lin H, Wang SH, Xiao WF, Endocr J 2010 57 201 209 10.1507/endocrj.K09E-205 20057162
21. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC, J Clin Endocrinol Metab 2000 85 4047 4052 10.1210/jc.85.11.4047 11095431 (Pubitemid 32055351)
22. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. Gilling-Smith C, Willis DS, Beard RW, Franks S, J Clin Endocrinol Metab 1994 79 1158 1165 10.1210/jc.79.4.1158 7962289 (Pubitemid 24342265)
23. Developmental origin of polycystic ovary syndrome-a hypothesis. Abbott DH, Dumesic DA, Franks S, J Endocrinol 2002 174 1 5 10.1677/joe.0.1740001 12098657 (Pubitemid 34830927)
24. Do animal models of polycystic ovary syndrome help to understand its pathogenesis and management? Yes, but their limitations should be recognized. Franks S, Endocrinology 2009 150 3983 3985 10.1210/en.2009-0652 19700609
25. Polycystic ovarian condition in the dehydroepiandrosterone -treated rat model: hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles. Anderson E, Lee GY, O'Brien K, Anat Rec 1997 249 44 53 10.1002/(SICI)1097-0185(199709)249:1<44::AID- AR6>3.0.CO;2-F 9294648 (Pubitemid 27391418)
26. Reduced intrafollicular androstenedione and estradiol levels in early-treated prenatally androgenized female rhesus monkeys receiving follicle-stimulating hormone therapy for in vitro fertilization. Dumesic DA, Schramm RD, Bird IM, Peterson E, Paprocki AM, Zhou R, Abbott DH, Biol Reprod 2003 69 1213 1219 10.1095/biolreprod.102.015164 12801996 (Pubitemid 37173854)